身体活動,食事,アルツハイマー病のリスク
Nikolaos Scarmeas1, Jose A Luchsinger, Nicole Schupf
1Taub Institute for Research in Alzheimer's Disease and the Aging Brain and Department of Neurology, Columbia University Medical Center, 622 W 168th St, New York, NY 10032, USA. ns257@columbia.edu
JAMA
|August 13, 2009
まとめ
地中海型ダイエットと定期的な身体活動を行うことは,アルツハイマー病 (AD) のリスクを大幅に低下させます. この2つのライフスタイル要因の組み合わせは,AD発症に対する保護効果を提供します.
科学分野:
- 神経科学は神経科学である.
- エピデミオロジー エピデミオロジー
- ゲロントロジーはゲロントロジーの学科です.
背景:
- アルツハイマー病 (AD) のリスクは,ライフスタイル要因の影響を受けます.
- 地中海型ダイエットと身体活動が独立してADリスクの低下と関連しています.
- ダイエットと運動がADリスクに与える影響は,まだ十分に研究されていない.
研究 の 目的:
- 地中海型ダイエットの遵守と身体活動のレベルとアルツハイマー病のリスクとの間の相乗効果的関連を調べる.
- ライフスタイルの組み合わせによる介入が,個々の成分よりもADに対するより大きな保護を提供しているかどうかを判断する.
主な方法:
- 1880人の認知的に健全な高齢者を対象とした前向きなコホート研究.
- ダイエット遵守と身体活動レベルは,検証された測定法を使用して評価されました.
- コックス比例リスクモデルは,アルツハイマー病の発生までの時間を分析し,共変数に調整した.
主要な成果:
- 地中海型ダイエットへのより高い遵守は,ADリスクの有意な減少と関連していました (HR=0.60).
- また,身体活動のレベルの増加は,独立してADリスクの低下と関連していた (HR=0.67は高い活動).
- 高いダイエットと高い身体活動の両方を遵守した個人は,ADの絶対リスクが大幅に低下したことを示しました (12%対19%).
結論:
- 地中海型ダイエットと身体活動の両方の遵守は,アルツハイマー病のリスクの低下と独立して関連しています.
- 健康的な食事と定期的な運動の組み合わせは,ADに対するシネージ的保護効果をもたらす可能性があります.
- これらの発見は,アルツハイマー病の予防のためのライフスタイル介入を支持しています.
関連する概念動画
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...